Genital Herpes: New Therapeutic Approaches Advance

New vaccines and a compound with new mechanism of action that are in early clinical trials suggest the poorly served antiherpes market could be rejuvenated in the next few years.

Herpes virus

Reports that a potential new trivalent vaccine against herpes simplex virus-2 (HSV-2) infection developed at the Perelman School of Medicine, University of Pennsylvania, has provided protection against herpes infection in early stage studies come at a time when other strategies are also starting to show promise against this public health problem.

HSV-2 causes genital herpes and is a major cause of morbidity worldwide, and a vaccine approach has not previously been...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip